Introducing a New Strategy on Bioequivalence in Ukraine


USAID's SAFEMed Bioequivalence Report provides an in-depth analysis of current and future legislative requirements for better governance of bioequivalence in Ukraine. Bioequivalence of medicines in Ukraine is not aligned with EU standards, and there are risks that Ukrainians may be exposed to sub-standard generic medicines that would not be allowed in EU states, damaging the trust of the general population toward the health care system. As part of the objectives of governance improvement and ensuring the availability of quality medicines, SAFEMed provides technical assistance to compare EU standards and best practices with the current state of bioequivalence in Ukraine. The work includes consultation with in-country expertise, evaluation of actual current practices, and in-depth analysis of current and future legislative requirements.